Capstone (CAPS) vs GeoVax Labs (GOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Capstone is the larger company by market cap ($1.3 million vs $985,459), about 1.4 times the size. Capstone converts more of its revenue into profit, with a net margin of -45.3% versus -862.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPS | GOVX |
|---|---|---|
| Share price | $1.44 | $1.81 |
| Market cap | $1.35M | $985.46K |
| 1-day change | -9.15% | -5.24% |
| EPS (TTM) | $-89.68 | $-15.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $46.88M | $2.49M |
| Revenue growth (YoY) | +4.47% | -37.06% |
| Net income (latest FY) | $-21.23M | $-21.46M |
| Gross margin | 23.02% | — |
| Operating margin | -23.43% | -869.34% |
| Net margin | -45.28% | -862.34% |
| 52-week high | $28.50 | $270.60 |
| 52-week low | $1.42 | $1.51 |
| Distance from 52-week high | -94.95% | -99.33% |
| Analyst consensus | none | none |
| Avg. price target upside | +108.33% | +452.49% |
| Average volume | 153.70K | 213.41K |
| Shares outstanding | 935.38K | 544.45K |
| Employees | 93 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Capstone is more profitable, keeping -45.3 cents of every revenue dollar as net income versus -862.3 cents for GeoVax Labs.
- Capstone grew revenue faster in its latest fiscal year (+4.47% vs -37.06%).
About Capstone
CAPS stock →Capstone Holding Corp., through its subsidiaries, engages in the distribution and installation of building products in the United States and Canada. It operates in two segments, TotalStone and Carolina Stone.
Health Care · Biotechnology: Pharmaceutical Preparations · 93 employees
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
CAPS vs GOVX FAQ
Which is bigger, Capstone or GeoVax Labs?
Capstone (CAPS) is larger, with a market capitalization of $1.35M compared with $985.46K for GeoVax Labs (GOVX).
Are Capstone and GeoVax Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.